2X1.F Abivax SA

Healthcare Biotechnology Frankfurt Exchange
81.50 EUR
Close of Nov 12, 2026
61.35 133.10
Market cap
EUR 7.13B
P/E
-
P/B
18.80x
ROE
-90.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 2X1.F undervalued?

Graham number

The Graham number of Abivax SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Abivax SA fundamental analysis

No fundamental analysis for Abivax SA yet.

Abivax SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Abivax SA

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in…

Full company profile